GlassScriptPhysician profile
Susan C Capelle
NPI 1275584872
$4,155.55
in general payments reported to CMS, 2019-2025
28 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Urology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $126 · 2021: $795 · 2022: $837 · 2023: $537 · 2024: $531 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.18 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,203.19 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $693.19 | 2019-2025 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $472.32 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $357.77 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $162.67 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $158.36 | 2019 | |
| Caldera Medical, INC | $155.23 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $107.97 | 2021-2022 | |
| Urovant Sciences INC | $107.90 | 2022 | |
| Therapeuticsmd, INC. | $95.12 | 2021-2022 | |
| Axonics, INC. | $90.00 | 2021-2023 | Axonics |
| Boston Scientific Corporation | $73.53 | 2019 | |
| Organon LLC | $68.12 | 2021-2023 | Nexplanon |
| Pfizer INC. | $55.18 | 2022-2024 | |
| Amgen INC. | $54.38 | 2022-2025 | Evenity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $45.53 | 2021-2023 | Slynd |
| Hologic Sales and Service, LLC | $42.05 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Myovant Sciences INC. | $29.87 | 2021-2022 | |
| Allergan, INC. | $23.38 | 2019-2020 | |
| Mission Pharmacal Company | $22.58 | 2020 | |
| Millicent US INC | $21.43 | 2025 | Intrarosa |
| Coloplast Corp | $19.64 | 2023 | |
| Merck Sharp & Dohme LLC | $17.24 | 2019 | |
| Daiichi Sankyo INC. | $16.89 | 2025 | Injectafer |
| Novo Nordisk INC | $16.30 | 2022 | |
| Roche Diagnostics Corporation | $15.99 | 2019 | |
| Virtus Pharmaceuticals LLC | $15.29 | 2022 | |
| Provepharm INC. | $14.43 | 2025 | Bludigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Capelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.